Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Search

Page Path

HOME
Search

Review

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

Jihyun An, Joo Hyun Sohn

Clin Mol Hepatol. 2023;29(Suppl):S268-S275. Published online December 20, 2022

DOI: https://doi.org/10.3350/cmh.2022.0437

View: 3049 Download: 190 Web of Science: 8 Crossref: 10

Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis

Yi-wen Shi, Jian-Gao Fan

Clin Mol Hepatol. 2023;29(Suppl):S228-S243. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0401

View: 3324 Download: 103

Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response

Silvia Sookoian, Carlos J. Pirola

Clin Mol Hepatol. 2023;29(Suppl):S184-S195. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0318

View: 3546 Download: 171 Web of Science: 8 Crossref: 8

Non-alcoholic fatty liver disease: Definition and subtypes

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(suppl):S5-S16. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0424

View: 5843 Download: 466 Web of Science: 22 Crossref: 25

Editorial

Adding to the confusion in more than just the name

Jacob George

Clin Mol Hepatol. 2023;29(4):973-976. Published online September 18, 2023

DOI: https://doi.org/10.3350/cmh.2023.0367

View: 1374 Download: 62 Web of Science: 3 Crossref: 4

Correspondence

Correspondence on Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(3):817-819. Published online May 17, 2023

DOI: https://doi.org/10.3350/cmh.2023.0155

View: 1697 Download: 43

Original Article

Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis

Min Jeong Park, Hayeon Kim, Myeong Gyu Kim, Kyungim Kim

Clin Mol Hepatol. 2023;29(3):693-704. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2022.0330

View: 2833 Download: 157 Web of Science: 3 Crossref: 3

Editorial

Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?

Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang

Clin Mol Hepatol. 2023;29(2):404-407. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0069

View: 2488 Download: 69 Web of Science: 2 Crossref: 2

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Kee-Huat Chuah, Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(2):401-403. Published online February 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0062

View: 2324 Download: 56 Web of Science: 1 Crossref: 2

Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?

Ho Soo Chun, Minjong Lee

Clin Mol Hepatol. 2023;29(2):377-380. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0061

View: 2268 Download: 93 Web of Science: 2 Crossref: 1

Review

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin

Clin Mol Hepatol. 2023;29(1):77-98. Published online October 13, 2022

DOI: https://doi.org/10.3350/cmh.2022.0237

View: 8530 Download: 612 Web of Science: 24 Crossref: 33

Snapshot

Personalized medicine in nonalcoholic fatty liver disease

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):935-938. Published online June 24, 2022

DOI: https://doi.org/10.3350/cmh.2022.0175

View: 3538 Download: 135 Web of Science: 4 Crossref: 4

Editorial

Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):806-809. Published online August 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0208

View: 2290 Download: 61

Review

Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen

Clin Mol Hepatol. 2022;28(4):790-801. Published online May 11, 2022

DOI: https://doi.org/10.3350/cmh.2022.0070

View: 6701 Download: 484 Web of Science: 40 Crossref: 43

Editorial

A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease

Seonghwan Hwang, Won Kim

Clin Mol Hepatol. 2022;28(3):478-480. Published online June 16, 2022

DOI: https://doi.org/10.3350/cmh.2022.0143

View: 2936 Download: 89

Original Article

Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis

Gang Xu, Yu-Min Wang, Miao-Miao Ying, Sui-Dan Chen, Zong-Rui Li, Hong-Lei Ma, Ming-Hua Zheng, Jian Wu, Chunming Ding

Clin Mol Hepatol. 2021;27(2):329-345. Published online January 20, 2021

DOI: https://doi.org/10.3350/cmh.2020.0261

View: 6687 Download: 222 Web of Science: 11 Crossref: 16

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseases

Yun Seok Kim, Sang Geon Kim

Clin Mol Hepatol. 2020;26(4):715-727. Published online September 22, 2020

DOI: https://doi.org/10.3350/cmh.2020.0173

View: 9092 Download: 261 Web of Science: 29 Crossref: 29

Review

Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology

Silvia Sookoian, Carlos J. Pirola

Clin Mol Hepatol. 2020;26(4):461-475. Published online September 10, 2020

DOI: https://doi.org/10.3350/cmh.2020.0136

View: 8152 Download: 275 Web of Science: 34 Crossref: 37

Editorial

Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease?

Ju Hyun Shim

Clin Mol Hepatol. 2020;26(2):183-184. Published online March 12, 2020

DOI: https://doi.org/10.3350/cmh.2020.0042

View: 4168 Download: 111 Web of Science: 6 Crossref: 6

Review

Recent research trends and updates on nonalcoholic fatty liver disease

Jeong-Ju Yoo, Won Kim, Moon Young Kim, Dae Won Jun, Sang Gyune Kim, Jong-Eun Yeon, Jin Woo Lee, Yong Kyun Cho, Sang Hoon Park, Joo Hyun Sohn

Clin Mol Hepatol. 2019;25(1):1-11. Published online August 8, 2018

DOI: https://doi.org/10.3350/cmh.2018.0037

View: 18533 Download: 716 Web of Science: 69 Crossref: 66

Original Article

Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis

Wataru Ando, Hiroaki Yokomori, Nobuhiro Tsutsui, Eigoro Yamanouchi, Yutaka Suzuki, Masaya Oda, Yutaka Inagaki, Katsuya Otori, Isao Okazaki

Clin Mol Hepatol. 2018;24(1):61-76. Published online November 20, 2017

DOI: https://doi.org/10.3350/cmh.2017.0030

View: 9204 Download: 170 Web of Science: 25 Crossref: 27

Review

NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs

Stephen Caldwell

Clin Mol Hepatol. 2017;23(2):103-108. Published online May 10, 2017

DOI: https://doi.org/10.3350/cmh.2017.0103

View: 11944 Download: 473 Web of Science: 30 Crossref: 30

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

The Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol. 2013;19(4):325-348. Published online December 28, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.4.325

View: 13061 Download: 158 Crossref: 94

Editorial

Noninvasive markers: a double-edged sword that stratifies nonalcoholic steatohepatitis

Goh Eun Chung, Donghee Kim

Clin Mol Hepatol. 2013;19(2):116-119. Published online June 27, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.2.116

View: 6749 Download: 91

Case Report

Severe steatohepatitis with hepatic decompensation resulting from malnutrition after pancreaticoduodenectomy

Eun Hui Sim, Jung Hyun Kwon, Se Young Kim, Seung Min Jung, Lee-So Maeng, Jeong Won Jang, Kyu Won Chung

Clin Mol Hepatol. 2012;18(4):404-410. Published online December 21, 2012

DOI: https://doi.org/10.3350/cmh.2012.18.4.404

View: 7241 Download: 83 Crossref: 13

3

Validity and reliability of the nonalcoholic fatty Liver diseases activity score (NAS) in Korean NAFLD patients and its correlation with clinical factors

Kyung-Hun Lee, M.D., Sang Hoon Park, M.D., Yu Jin Kim, M.D., Kyung Rim Huh, M.D., Kwang Seon Min M.D., Sun-Young Jun M.D., Kyoung Oh Kim, M.D., Cheol Hee Park, M.D., Taeho Hahn, M.D., Kyo-Sang Yoo, M.D., Jong Hyeok Kim, M.D., Myung-Seok Lee, M.D., Choong Kee Park, M.D.

Clin Mol Hepatol. 2010;16(1):29-37. Published online March 26, 2010

DOI: https://doi.org/10.3350/kjhep.2010.16.1.29

PDF

View: 5041 Download: 52 Crossref: 2

Current status of Liver diseases in Korea: nonalcoholic fatty Liver disease

Sang Hoon Park

Clin Mol Hepatol. 2009;15(60):34-39. Published online December 31, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.S6.S34

PDF

View: 7108 Download: 45 Crossref: 19

2

Pathology of nonalcoholic steatohepatitis

Yoon Mi Jeen , So Young Jin

Clin Mol Hepatol. 2009;15(2):122-130. Published online June 30, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.2.122

PDF

View: 4998 Download: 56 Crossref: 3

5

Nonalcoholic Steatohepatitis

So-Young Jin

Clin Mol Hepatol. 2006;12(3):455-459. Published online January 1, 2000

PDF

View: 2546 Download: 20

3

Antioxidant Status in Nonalcoholic Steatohepatitis

Kyung Sik Park, M.D., Byoung Kuk Jang, M.D., Ki Min Kwon, M.D., Woo Jin Chung, M.D., Kwang Bum Cho, M.D., Jae Seok Hwang, M.D., Sung Hoon Ahn, M.D., Kyo Cheol Mun, M.D. and Young Hwan Kim, M.D.

Clin Mol Hepatol. 2005;11(2):135-143. Published online January 1, 2000

PDF

View: 2568 Download: 26

1 | 2 |

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Impact Factor

8.9
First decision

09 Days

Publication after acceptance

04 Days

*Last 12 months

MOST VIEWED MOST CITED

MOST VIEWED (Last 6 months)

Viewed By 5272	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5216	MAFLD: How is it different from NAFLD?
Viewed By 5117	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3838	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3772	Global incidence and prevalence of nonalcoholic fatty liver disease

MOST CITED (2022-2024)

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051 FAX: +82-2-703-0071 E-mail: kasl@kams.or.kr

Copyright © The Korean Association for the Study of the Liver.

COUNTER

TODAY : 1387

TOTAL : 1790130